| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Platelet-activating factor receptor (PAFR) and tyrosinase (EC 1.14.18.1).
|
|---|---|
| ln Vitro |
In vitro, benzoyloxypaeoniflorin inhibits platelet aggregation and blood coagulation, contributing to improved blood circulation. It suppresses pro-inflammatory cytokines and reduces oxidative stress. The compound functions as a tyrosinase inhibitor (EC 1.14.18.1), an enzyme involved in melanin biosynthesis. It also acts as a platelet aggregation inhibitor. The compound's anti-inflammatory activity is mediated through modulation of inflammatory pathways including suppression of pro-inflammatory cytokines.
|
| ln Vivo |
In vivo, benzoyloxypaeoniflorin has demonstrated neuroprotective effects, protecting neurons from injury. Its anti-inflammatory and analgesic activities have been observed in animal models. The compound contributes to improving blood circulation through inhibitory effects on platelet aggregation and blood coagulation. Detailed in vivo efficacy data are limited as the compound is primarily a research-grade natural product.
|
| Enzyme Assay |
Receptor binding assays for PAFR (platelet-activating factor receptor) can be performed using membrane preparations from cells expressing PAFR. Membranes are incubated with radiolabeled [3H]-PAF and varying concentrations of benzoyloxypaeoniflorin (0.1-100 microM) in binding buffer (50 mM Tris-HCl, pH 7.4, containing 0.25% BSA, 10 mM MgCl2, and 1 mM CaCl2) at 4degC for 60-120 minutes. Non-specific binding is determined in the presence of 1-10 microM unlabeled PAF. Bound and free ligand are separated by filtration through GF/B filters. Radioactivity is counted and binding parameters are calculated. Tyrosinase inhibition assays: mushroom tyrosinase (0.5-1.0 microg) is incubated with L-DOPA (0.5-2 mM) and varying concentrations of benzoyloxypaeoniflorin (0.1-100 microM) in phosphate buffer (pH 6.8) at 25degC for 10-30 minutes. Dopachrome formation is monitored at 475 nm. IC₅0 values are calculated from dose-response curves.
|
| Cell Assay |
Platelet aggregation assays are performed using platelet-rich plasma (PRP) prepared from human or animal blood. PRP is obtained by centrifugation of citrated blood at 200-300 × g for 15-20 minutes. Platelet aggregation is induced by ADP (5-10 microM), collagen (2-5 microg/mL), or arachidonic acid (0.5-1 mM). Benzoyloxypaeoniflorin is added to PRP at concentrations ranging from 1-100 microM and incubated for 2-5 minutes before addition of the aggregating agent. Aggregation is monitored using a platelet aggregometer, and percent inhibition of aggregation is calculated. Anti-inflammatory activity is assessed in macrophage cell lines (e.g., RAW 264.7) by measuring inhibition of LPS-stimulated NO production (Griess assay) and cytokine release (ELISA).
|
| Animal Protocol |
C57BL/6 or other rodent models are used to evaluate anti-inflammatory and anti-thrombotic activities. For anti-inflammatory studies, animals are treated with benzoyloxypaeoniflorin orally or intraperitoneally at doses ranging from 10-100 mg/kg, followed by induction of inflammation using carrageenan (paw edema) or LPS (systemic inflammation). Paw swelling is measured, and inflammatory markers (TNF-alpha, IL-6, IL-1beta) are quantified in serum or tissue. For anti-thrombotic studies, the compound is administered and platelet aggregation is measured ex vivo or in vivo using models such as collagen-induced thrombosis. Neuroprotective effects are evaluated in models of cerebral ischemia or neurotoxin-induced neuronal damage. Detailed protocols are not standardized for this compound.
|
| ADME/Pharmacokinetics |
Benzoyloxypaeoniflorin has molecular formula C30H32O13 and molecular weight 600.57. The benzoyloxy group enhances lipophilicity, which may improve oral bioavailability and tissue distribution. Solubility is limited in aqueous solutions; DMSO or ethanol is typically used for stock solutions. The compound is stable when stored at 2-8degC. Metabolism likely involves deglycosylation and further conjugation.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are reported for benzoyloxypaeoniflorin. As a natural product from Paeonia species, it is presumed to have a favorable safety profile. However, high doses may have effects that have not been systematically evaluated. The compound is for research use only and not for human consumption. Standard safety precautions should be observed when handling.
|
| References |
|
| Additional Infomation |
β-Benzoyloxypaeoniflorin is a monoterpene glycoside with the molecular formula C30H32O13, isolated from various Paeonia species. It functions as a plant metabolite, a platelet aggregation inhibitor, and an EC 1.14.18.1 (tyrosinase) inhibitor. It is a 4-hydroxybenzoic acid ester, an O-acyl carbohydrate, a β-D-glucoside, a bridging compound, a cyclic acetal, a lactone alcohol, and a monoterpene glycoside.
β-Benzoyloxypaeoniflorin has been reported in previous literature in Paeonia suffruticosa. Benzoyloxypaeoniflorin (beta-benzoyloxypaeoniflorin) is a natural monoterpene glycoside isolated from various Paeonia species. It is a benzoylated derivative of paeoniflorin with enhanced lipophilicity and pharmacological potency. The compound exhibits anti-inflammatory, analgesic, antioxidant, neuroprotective, and anti-thrombotic activities. Its primary research applications include studies on platelet aggregation inhibition and blood coagulation, as well as investigations into anti-inflammatory mechanisms. Benzoyloxypaeoniflorin is not an approved therapeutic agent; it is a research-grade natural product used for pharmacological studies. |
| Molecular Formula |
C30H32O13
|
|---|---|
| Molecular Weight |
600.5673
|
| Exact Mass |
600.184
|
| CAS # |
72896-40-3
|
| PubChem CID |
21631107
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.0 g/cm3
|
| Boiling Point |
789.1±0.0 °C at 760 mmHg
|
| Flash Point |
258.6±0.0 °C
|
| Vapour Pressure |
0.0±0.0 mmHg at 25°C
|
| Index of Refraction |
1.699
|
| LogP |
5.22
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
43
|
| Complexity |
1110
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
C[C@]12C[C@@]3([C@@H]4C[C@]1([C@@]4([C@H](O2)O3)COC(=O)C5=CC=C(C=C5)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)COC(=O)C7=CC=CC=C7)O)O)O)O
|
| InChi Key |
VIWQCBZFJFSCLC-HRCYFWENSA-N
|
| InChi Code |
InChI=1S/C30H32O13/c1-27-13-29(37)19-11-30(27,28(19,26(42-27)43-29)14-39-24(36)16-7-9-17(31)10-8-16)41-25-22(34)21(33)20(32)18(40-25)12-38-23(35)15-5-3-2-4-6-15/h2-10,18-22,25-26,31-34,37H,11-14H2,1H3/t18-,19-,20-,21+,22-,25+,26-,27+,28+,29-,30+/m1/s1
|
| Chemical Name |
[(1R,2S,3R,5R,6R,8S)-3-[(2S,3R,4S,5S,6R)-6-(benzoyloxymethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-6-hydroxy-8-methyl-9,10-dioxatetracyclo[4.3.1.02,5.03,8]decan-2-yl]methyl 4-hydroxybenzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~166.51 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.16 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.16 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.16 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6651 mL | 8.3254 mL | 16.6508 mL | |
| 5 mM | 0.3330 mL | 1.6651 mL | 3.3302 mL | |
| 10 mM | 0.1665 mL | 0.8325 mL | 1.6651 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
